Up-regulation of Core 1 Beta 1, 3-Galactosyltransferase Suppresses Osteosarcoma Growth with Induction of IFN-γ Secretion and Proliferation of CD8+ T Cells

Author:

Chen Haidan12,Cai Huili3,Tang Lei12,Cegang Fu14,Zhao Hongwei1,Wang Bofei1,Jia Siyu1

Affiliation:

1. Department of Spinal Surgery Ward, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang, Wuhan Province, China

2. Ningxia Medical University, Yinchuan, Ningxia, China

3. Department of Hematology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang, Wuhan Province, China

4. Department of Orthopedics, Haikou Orthopedic and Diabetes Hospital, Haikou Orthopedic and Diabetes Hospital of Shanghai Sixth People's Hospital, Haikou, Hainan Province, China

Abstract

Purpose: Abnormal glycosylation often occurs in tumor cells. T-synthase (core 1 beta 1,3- galactosyltransferase, C1GALT1, or T-synthase) is a key enzyme involved in O-glycosylation. Although T-synthase is known to be important in human tumors, the effects of T-synthase and T-antigen on human tumor responses remain poorly defined. Methods: In this study, a T-synthase-specific short hairpin RNA (shRNA) or T-synthase-specific eukaryotic expression vector(pcDNA3.1(+)) was transfected into murine Osteosarcoma LM8 cells to assess the effects of T-synthase on T cells and cytokines. Results: The up-regulation of T-synthase promoted the proliferation of osteosarcoma cells in vitro, but it promoted the proliferation of tumor initially up to 2-3 weeks but showed significant growth inhibitory effect after 3 weeks post-implantation in vivo. Osteosarcoma cells with high T-synthase expression in vitro promoted the proliferation and inhibited the apoptosis of CD8+ T cells. Further, T-synthase upregulation promoted CD8+ T-cell proliferation and the increased production of CD4+ T cell-derived IFN-γ cytokines to induce the increased tumor lethality of CTLs. Conclusion: Our data suggest that high T-synthase expression inhibits tumor growth by improving the body's anti-tumor immunity. Therefore, using this characteristic to prepare tumor cell vaccines with high immunogenicity provides a new idea for clinical immunotherapy of osteosarcoma.

Funder

National Natural Science Foundation of China

Youth Fund Project of Hainan Natural Science Foundation

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Reference59 articles.

1. Wedekind M.F.; Wagner L.M.; Cripe T.P.; Immunotherapy for osteosarcoma: Where do we go from here? Pediatr Blood Cancer 2018,65(9),e27227

2. Rickel K.; Fang F.; Tao J.; Molecular genetics of osteosarcoma. Bone 2017,102,69-79

3. Casali P.G.; Bielack S.; Abecassis N.; Aro H.T.; Bauer S.; Biagini R.; Bonvalot S.; Boukovinas I.; Bovee J.V.M.G.; Brennan B.; Brodowicz T.; Broto J.M.; Brugières L.; Buonadonna A.; De Álava E.; Dei Tos A.P.; Del Muro X.G.; Dileo P.; Dhooge C.; Eriksson M.; Fagioli F.; Fedenko A.; Ferraresi V.; Ferrari A.; Ferrari S.; Frezza A.M.; Gaspar N.; Gasperoni S.; Gelderblom H.; Gil T.; Grignani G.; Gronchi A.; Haas R.L.; Hassan B.; Hecker-Nolting S.; Hohenberger P.; Issels R.; Joensuu H.; Jones R.L.; Judson I.; Jutte P.; Kaal S.; Kager L.; Kasper B.; Kopeckova K.; Krákorová D.A.; Ladenstein R.; Le Cesne A.; Lugowska I.; Merimsky O.; Montemurro M.; Morland B.; Pantaleo M.A.; Piana R.; Picci P.; Piperno-Neumann S.; Pousa A.L.; Reichardt P.; Robinson M.H.; Rutkowski P.; Safwat A.A.; Schöffski P.; Sleijfer S.; Stacchiotti S.; Strauss S.J.; Sundby Hall K.; Unk M.; Van Coevorden F.; van der Graaf W.T.A.; Whelan J.; Wardelmann E.; Zaikova O.; Blay J.Y.; Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018,29(Suppl. 4),79-95

4. Ługowska, I.; Pieńkowski, A.; Szumera-Ciećkiewicz, A.; Koseła- Paterczyk, H.; Teterycz, P.; Głogowski, M. The long-term treatment outcomes of adult osteosarcoma. Pol Merkuriusz Lek 2017,42,158-164

5. Harrison D.J.; Geller D.S.; Gill J.D.; Lewis V.O.; Gorlick R.; Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 2018,18(1),39-50

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3